In conclusion, downregulation of ARHGEF26 in podocytes and glomeruli could potentially impair renal microvasculature and alter podocyte morphology and barrier function, consequently compromising the integrity of the glomerular filtration barrier and hastening DKD progression. This evidence concerns the gene ARHGEF26 and diabetic kidney disease.